text:
Smart homeowners know the best investment they can make is in the value of their properties, which is intrinsically linked the larger community.
The Community Preservation Act (CPA) is exactly the kind of investment this city needs to make to maintain the revitalization we’ve enjoyed in recent years.
After the forum hosted by the Mack Park Neighborhood Association last week, I’m very confident about supporting CPA (voting YES on question #4), which would add 1% to Salem property taxes to leverage state funds for parks, open spaces, historic preservation and affordable housing. The State would match the funds for between 25% and 50%. The tax would represent about $30/year (12.1 cents/day), and only from property owners who can afford it.
The opposition maintains that the CPA would make Salem less affordable to live. The rewritten CPA exempts four-person households earning $78,240 or below, and $68,460 for a senior-citizen household of one. The first $100,000 in property value is exempt for EVERYONE.
CPA funds are for earmarked for 1) improving parks and open spaces; 2) preserving historic landmarks; and 3) keeping our community affordable. Think of repairing the dilapidated fence around Salem Common, or making housing affordable for community workers like teachers and firefighters. Two CPA proponents are Mickey Northcutt, Executive Director of the North Shore Community Development Coalition, and Christine Sullivan, CEO of the Enterprise Center, two people invested in the value of affordable housing and business growth in Salem.
Sullivan pointed out, "The future of our city relies on having a good quality of life…We are leaving $80,000 to $200,000 in the pot for other communities to get." Fully 148 Massachusetts communities are CPA recipients, including Gloucester. Salem pays into CPA; let’s protect what we have already, while adding value to the entire community. All for 12.1 cents a day.
Sara Maurno, resident and homeowner


text:
Evolving landscapes in multiple sclerosis research: adaptive designs and novel endpoints
Multiple Sclerosis and Demyelinating Disorders volume 1, Article number: 2 (2016)
The increasing amount of highly effective treatment options in relapsing forms of multiple sclerosis (MS) requires innovative clinical trial design strategies. These strategies may encompass the application of adaptive designs as well as the adoption of innovative primary outcome measurements. The offered advantages would include, among others, shorter study follow-up periods and reduction in the number of patients either on placebo or on non-suitable dosages of the small molecules or biological products under examination. Changing the primary endpoint during the study conduct additionally represents an option, when the primary endpoint originally is either a composite endpoint of Magnetic Resonance Imaging (MRI) and clinical variables or a unitary endpoint of clinical variables. The new outcome measurement of no-evidence-of-disease activity (NEDA) – the former disease activity free (DAF) status, might represent an attractive approach and NEDA may become a new standard for clinical trials in relapsing MS (RMS), particularly for pivotal Phase III trials, though also earlier phase trials and exploratory clinical research might benefit from this endpoint. Future studies in RMS could incorporate NEDA as a primary endpoint and utilize the adaptive design methodology in order to reduce the sample size and the duration of new therapeutic agents’ clinical development.
Table of contents
Adaptive study design methodology in the clinical development of products targeting multiple sclerosis 6
Learning, confirming or both? 8
An interim change of the primary dependent variable – use of the No-Evidence-of-Disease Activity [NEDA] status 9
Competing interests 15
Author contributions 15
Author information 15
Since the commercial availability of disease-modifying treatments (DMTs) for the treatment of relapsing multiple sclerosis (RMS), significant changes have occurred in the diagnosis and management of multiple sclerosis (MS), with a significant impact on the clinical research in this area . The year 1993 saw the release of the first disease-modifying drug, Betaseron® and this was accompanied by increased research and attention on the disease. Since this time, patients have developed an increasingly sophisticated and accurate understanding of MS . Additionally, the increasing number of clinical trials has allowed investigators to observe changes in terms of characteristics and behaviors of clinical trial populations in RMS [3, 4]. In particular, patient populations in recent studies are characterized by a lower clinical disease activity level at the time of entry into clinical trials in comparison to the past. These observations limit the utility of historical data for effect size estimations based upon either the number or time to the events or other aspects of disease progression as points of interest. The reasons for observations of improved placebo response across many indications are variable, but within RMS this shift might be related mainly to two factors:
The adoption of McDonald criteria that allows shortening significantly the timeframe from the status of a clinically isolated syndrome to the diagnosis of MS .
Given these changes in patient phenotype, two main challenges can be identified when designing a future trial in MS:
The classical clinical endpoints, recommended by European Medicines Agency’s (EMA’s) Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis , may not be sensitive enough to demonstrate additional efficacy with respect to the current standard treatments in head-to-head comparison studies. Even if statistically significant differences are demonstrated within primary study data sets it could be argued whether the detected difference would constitute any clinically meaningful improvement. Clinical trials with an add-on treatment design might face similar challenges.
The chance of detecting differences with respect to placebo in a population with low disease activity is reduced.
Any shift during the clinical development with a clinical trial conducted in Phase II on a study population with low disease activity towards a specific population with high disease activity, such as in a Phase III confirmatory trial, may be accompanied by incorrect assumptions regarding the nature of the dose-exposure-response relationships, erroneous power calculations for planned sample sizes, and differences in the hierarchy of primary and secondary measures. This may also incur potentially significant regulatory restrictions in the drug label as a consequence of changes in the patient population and in the nature of assessments occurring within the development program.
New design strategies are therefore required to handle this evolution in patient presentation and progression, given that trial methodologists historically have had limited choices for a Phase III trial. One standard option has been to increase the sample size and the number of subjects on placebo, introducing potential ethical issues . Alternatively, use of a head-to-head comparative or add-on treatment study designs, both designs with active treatment groups, addresses the ethical issue of exposure to placebo, but adds further challenges due to the expected small difference in efficacy between two active treatments using traditional measures. From this original situation, creative solutions have been sought and employed which go beyond these two standard options and resolve some of their inherent shortcomings.
Among others, a strategy of replacement of the current standard primary endpoints with a new one could produce an increased level of sensitivity without the loss of specificity and reliability. In addition, especially in early exploratory studies, some advantageous options include:
Enrichment maneuvers in selecting the patient population, ensuring high disease activity status, for example through the use of a run-in period during which monthly Magnetic Resonance Imaging (MRI) scans are performed.
Use of an adaptive design in order to prospectively allow the change of a dependent variable or sample size based upon interim information during the study.
Use of surrogate MRI markers as primary outcomes, or as outcomes that can be used for dose selection purposes antecedent to longer-term studies evaluating clinical outcomes.
For the purpose of this article, the potential benefits offered by adaptive study designs and new outcome measures will be presented in detail.
Adaptive study design methodology in the clinical development of products targeting multiple sclerosis
Adaptive designs have received attention in the last few years by both the pharmaceutical/biotechnology industries and health authorities/regulatory agencies. Adaptive clinical design methodology, and the terminology to describe this methodology, has evolved over the years . Interchangeable terms historically have included adaptive, sequential, flexible, self-designing, multi-stage, dynamic and response driven models . Differences in terminology have contributed to inconsistent and confusing perspectives regarding benefits and potential disadvantages of these designs.
For the pharmaceutical and biotechnology industries, adaptive designs represent a diverse methodology with the common purpose of improving efficacy in the clinical development of drugs, with additional advantages in enhancing efficiency by reducing the cost and time components associated with drug development. Generally aggregated under the umbrella of “learning phase” versus “confirmatory phase” investigations, a portfolio of different adaptive designs support different objectives, and range in maturity from decades old methodology (for example, group sequential designs) to more recent and relatively underutilized study designs such as the use of seamless Phase II/III studies . Frequently, combinations of two or more approaches are encountered as shown in Table 1.
However, debate and discussion have followed the publication of recent Food and Drug Administration (FDA) guidance on adaptive designs . While this guidance recognizes the urgent need for new drug development tools, and sets a standard template for adaptive designs, it also emphasizes potential risks in the introduction of bias through the use of an adaptive study design methodology. According to the FDA guidance, an adaptive design should possess three features:
It is a prospectively planned modification of one or more specified element(s) of study design or hypotheses.
The modification is performed in a pre-specified manner based on an interim analysis of data from subjects in the study, at one or more times during the trial.
The interim analyses of accumulated study data are performed at pre-specified time points, in a fully blinded or unblinded manner, and can occur with or without formal statistical hypothesis testing.
As opposed to traditional fixed design trials, adaptive trials use accumulated data to modify some aspects of the ongoing trial, with the goal of preserving the validity and integrity of the trial. Frequently, adaptive design methodology requires a commensurate increases in study simulations, unique methods of trial management, and occasionally less than intuitive methods of analyses and interpretation. It is axiomatic that the complexity of an adaptive design must not exceed the available infrastructure to support its design and execution. Low complexity adaptive designs within an environment of well-established infrastructure and processes yield the best prospects for success.
Learning, confirming or both?
The utility of adaptive clinical trial methodology should be especially seen in the context of exploratory research and proof of concept trials, although there have been adaptive trials submitted as a component of marketing authorization . In a drug development program, pure exploration is usually the theme in early phase studies, where the dose-exposure-response relationships are speculative, and the clinical phenotype of the intended patient population and the primary efficacy endpoint are under study. Adaptation for sample size estimation, the discontinuation of uninformative dosage groups, or enrichment of the patient sample represent the most common utilizations. Once preliminary data supports the Proof-of-Concept, then a large-scale, randomized, well-controlled and more traditional confirmatory trial may be pursued.
In the central nervous system (CNS) area there are examples reported in the literature of drug development programs that utilized exploratory adaptive designs prior to continuing the drug development program or launching registration trials. A prominent example of this is acute migraine trials . More complex adaptive designs may include both patient adaptation and dose adaptation, incorporating the flexibility to re-estimate the sample size or the selected dose arm(s) .
An adaptive design may combine different phases of clinical trials; for example, the seamless adaptive Phase II/III design might be envisioned to combine Phase II and Phase III trials into one trial without a time gap between the two phases.
Beyond the use of group sequential designs, other adaptive design approaches within the neurological spectrum of disorders are less frequently encountered, although new entrants, particularly for adaptive randomization purposes, have been recently reported . Adaptive designs within MS are limited to very few examples as reported in the literature. Most frequently, the sample size estimation will be adapted in relation to the baseline disease activity of a limited group of subjects already randomized at the time of the interim analysis for this purpose .
There are, however, some other examples on how the adaptive design methodology can be applied to clinical development in MS. One of these is the BOLD study, a Phase II study with an adaptive, dose-ranging design . In this study, an adaptive design was chosen to characterize the dose–response curve of the study drug. In a first period of study (“Period 1”), three doses of study drug and placebo were tested for MRI-supported efficacy. Based on an interim analysis after 3 months of treatment, two additional active doses for a second period of the study (“Period 2”) were selected, thus optimizing the overall determination of the dose–response curve using 5 data points from active treatment doses along with placebo. The doses were kept blinded. The use of this design allowed for the determination of the optimal dose for later Phase III studies. The choice of placebo as a treatment control was considered essential to obtain information on the specific versus non-specific effects of the active treatment, and provided the best way of evaluating the efficacy, safety and tolerability profiles of the study drug. The use of an adaptive design strategy contributed to a significant reduction in placebo exposure, both in terms of the number of patients and in regards to study duration, compared to conventional trial models.
The structural and analytic aspects of the study conducted by Selmaj et al. have resemblance to other studies within neurological conditions such as amyotrophic lateral sclerosis (ALS), in which a two-stage seamless design is utilized in order to incorporate information regarding dose–response into a subsequent phase of the investigation . With appropriate modifications to the design structure and taking into consideration the endpoints and disease features, these data might be informative for future RMS studies.
An interim change of the primary dependent variable – use of the No-Evidence-of-Disease Activity [NEDA] status
The FDA guidance mentions the option of adaptation for endpoint selection based on interim estimates of treatment effect. Primary endpoint revision usually takes one of two forms:
Replacement of the designated primary endpoint with an entirely new endpoint, or
Modification of the primary endpoint by adding or removing data elements to the endpoint (e.g., the discrete event types included in a composite event endpoint).
Therefore, one of the possible endpoint scenarios uses a composite endpoint instead of a unitary primary endpoint.
The selection of composite endpoints has also been regarded as “a useful strategy” for registration of pharmaceuticals in the International Conference on Harmonisation (ICH) E9 guideline. It has long been recognized within other therapeutic areas that using a composite endpoint to enhance prospects for signal detection at a desired level of statistical significance is often accompanied by potential distortions in the nature and magnitude of treatment effects. This is primarily related to an asymmetry in the clinical importance of various parameters constituting the composite – i.e., frequent, less clinically important outcomes can drive the effect of therapy on any composite . Therefore, the regulatory requirements for the use of composite endpoints have been specified by the EMA Committee for Proprietary Medicinal Products (CPMP) .
According to the CPMP document, the use of a composite endpoint in a clinical trial is usually justified if the following assumptions are respected:
The individual components of the composite are clinically meaningful and of similar importance to the patient .
The expected effects on each component are similar, based on biological plausibility . Accordingly, regulatory guidelines also require the use of components for which it can be assumed that treatment will beneficially influence them in a similar way.
The clinically most important components of composite endpoints should at least not be affected negatively (no worsening of the clinical condition as measured by the component).
As a consequence, regulatory authorities require that each component of a composite endpoint be analyzed separately  to assist in the interpretation of treatment effect, even if the composite is statistically significant.
In MS, the disease-activity-free (DAF) status or as more recently called, the no-evidence-of-disease activity (NEDA) status, has become a new treatment goal in daily clinical practice, and is used for decision making on treatment changes or dose adaptations for current treatments . NEDA, a composite measure of disease activity, is currently defined only by 3 parameters:
Absence of new or enlarging T2 legions or T1 gadolinium-enhancing lesions on MRI.
Absence of sustained Expanded Disability Status Scale (EDSS) score progression.
Absence of any clinical relapse.
The concept of NEDA however, in the combination of the three variables as listed above or with any additional parameter proposed (NEDA-4), is currently lacking any standardization in terms of frequency of assessments and time period of observation. It is only recommended that NEDA should be evaluated within a given time frame of at least 1 year. Under these circumstances, the NEDA status could be strongly influenced by the duration of the study, the disease activity present at baseline, and the frequency of preplanned assessments This might not only be particularly relevant for the MRI component, but also for the clinical components for which the observation of disease progression is directly in relationship to the duration of the observational period. Indeed, a newly published research aimed to establish a reasonable study duration, as for the predictive value of this parameter on the long-term disease activity, determined that with an observational period of 2 years, NEDA can predict disability at 7 years almost as well as at 5 years .
All 3 parameters defining NEDA status represent different aspects of the disease activity in MS, and considering them together as representation of the disease activity increase the sensitivity for detecting evidence of disease activity, as measurable nowadays. The choice of NEDA as new outcome measurement, as defined by a composite of the 3 parameters, increases statistical precision and efficiency, with beneficial effects on sample size and study duration. The use of NEDA thus builds upon a tradition of combining imaging and clinical parameters in RMS where such combinations are thought to provide more sensitive outcome measures .
However, composite endpoints are associated with both clinical and biostatistical encumbrances, as shown already  in other therapeutic areas, and emphasized by the CPMP document  as well. It is therefore reasonable to approach their construction in MS with comparable caution. Similarly, there are strong arguments in the recent literature against the use of NEDA as a primary outcome in clinical trials designated for regulatory approval purposes , even if it’s recognized as an important goal for treating individual patients with relapsing disease or as a method for selecting the most appropriate therapy to move forward into confirmatory trials. In addition, the high variability of disease progression is neglected by this outcome measure. While Imitola  argues that the concept of NEDA might not be a realistic outcome for patients with MS, especially with increasing duration of disease, NEDA might demonstrate the most utility during the early stages of relapsing-remitting phase. Indeed, since none of the current available treatments for RMS represents a “cure” of the disease, they can only be called disease modifying treatments (DMTs). DMTs are able only to reduce the frequency and severity of relapses, extend the time intervals between relapses, and slow progression to permanent disability . Thus, in the long-term perspective very few subjects will maintain the status of NEDA, as the disease will progress even under treatment with DMTs.
Another potential downside in the use of this outcome lies in the risk of the overall measure being driven by the event with the greatest level of activity, as opposed to all events equally, thus violating the symmetry principle required for composite endpoints. Indeed, the disease activity free status might represent a reflection of only MRI defined activity events in trials in RMS where the composite has been employed, without balancing between frequency of assessments and the likelihood for observed findings within the MRI component as compared to the clinical ones. This risk is discussed by Nixon et al. , who states how some analytical adjustment may be required to account for the dominance of one component measure when the overall composite endpoint is driven to a large extent by MRI outcomes, with minimal contribution from clinical measures. Such unbalance is further emphasized by the number of observational time points used, if the number of MRI time points is higher than those for clinical assessments. MRI assessments present a higher sensitivity than clinical assessments, and disease progression in terms of clinical assessments is less likely to occur than disease progression shown by MRI. Indeed, if NEDA is used as a primary endpoint in a Phase III confirmatory trial, there is a risk of simply reproducing the results of a Phase II (MRI-driven) study instead of producing novel clinical evidence of treatment efficacy, if MRI impact is not properly weighted, because relapses are rare events and also disease progression develops very slowly over time. Although the utility of NEDA status endpoint in early phase interventional research, as well as in observational studies, is easily recognizable, further discussion with health authorities is required to enable inclusion of this outcome measure in the guidelines on new entities’ clinical development and registration (i.e. potentially pivotal) investigations in RMS. Due to its peculiar variability, it should be considered that the use of NEDA as a new primary endpoint from a methodological viewpoint may significantly affect sample size estimation, and it may also introduce a challenge in weighing each component in order to avoid unbalance and bias in estimation of comparative effects. Nevertheless, if properly used, NEDA would represent a powerful new primary endpoint even in pivotal Phase III trials, circumnavigating many of the current statistical challenges inherent in clinical-based endpoints.
Over the past 20 years, significant changes have occurred in the diagnosis and management of MS, with a significant impact on clinical research in this area. Additionally, the disease-related characteristics of patients presenting for evaluation in prototypical interventional studies has changed. The combination of novel DMTs along with a change in the clinical trials environment, mandate examination of different clinical trial methodologies. These include structural modifications in study design as well as the creation of novel pharmacodynamic and disease-related endpoints. The advent of new effective therapies in particular has made the use of placebo in trials lasting more than 6 months difficult to justify clinically, although methodological rigor precludes the sole use of active control comparative trials as a basis for deducing evidence of efficacy and safety.
Research in RMS is focusing on more sensitive clinical outcomes and study designs which can more efficiently evaluate the dose-exposure-response relationship of innovative therapies in early phase clinical trials, while simultaneously reducing the number of patients exposed to ineffective treatments in clinical programs. We have identified the recently proposed concept of “No-evidence-of disease-activity” (NEDA) status as a possible new parameter to be used in conjunction with adaptive trial designs to investigate the efficacy of new treatment strategies in RMS. Despite several limitations that the disease itself imposes for endpoint qualification and despite the prudent approach of health authorities towards the use of adaptive design for later phase investigations, the prospect of employing an adaptive design for endpoint selection based on interim estimate of treatment effect represents an attractive and plausible program option, even in pivotal Phase III trials. The use of NEDA as an endpoint deserves further evaluation for future exploratory studies in MS. Particular attention should be given to the methodological aspects of this endpoint, including the duration of the observational period and the weighing of each single component. Further methodological research and modeling are needed, as well as a full standardization of NEDA as an endpoint, before this can be universally accepted as a primary endpoint in future pivotal trials.
central nervous system
Committee for Proprietary Medicinal Products
disease modifying treatments
expanded disability status scale
European Medicines Agency
Food and Drug Administration
International Conference on Harmonisation
magnetic resonance imaging
relapsing multiple sclerosis
Cutter G, Kappos L. Clinical trials in multiple sclerosis. Handb Clin Neurol. 2014;122:445–53. doi:10.1016/B978-0-444-52001-2.00019-4.
Kraft GH, McMullen KA, AM B. The changing face of multiple sclerosis: Differences in gender and symtoms over a 27-year period. Int J MS Care. 2009;11(S2):4.
Uitdehaag BM, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin. 2011;27(8):1529–37. doi:10.1185/03007995.2011.591370.
Nicholas R, Straube S, Schmidli H, Schneider S, Friede T. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler. 2011;17(10):1211–7. doi:10.1177/1352458511406309.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–6. doi:10.1002/ana.20703.
Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009;15(10):1175–82.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(4):770–82.
Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs. 2003;63(15):1525–33.
Frohman EM, Havrdova E, Lublin F, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006;63(4):614–9.
Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology. 2010;75(4):302–9.
Pakdaman H, Sahraian MA, Fallah A, et al. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol Scand. 2007;115(6):429–31.
Hughes R, Francis G. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56(12):1628–36.
Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944–53.
Garcea O, Villa A, Cáceres F, et al. Early treatment of multiple sclerosis: a Latin American experts meeting. Mult Scler. 2009;15(3):S1–12.
O'Connor P, Devonshire V. The use of disease-modifying agents in multiple sclerosis—by the Canadian network of MS clinics. Can J Neurol Sci. 2008;35(2):127–32.
Karussis D, Biermann LD, Bohlega S, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol. 2006;13(1):61–71.
National Multiple Sclerosis Society USA (NMSS), “Disease management consensus statement [online],” 2015, http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color. Accessed 9 July 2015 and 14 March 2016
Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis, Rev 2. 26 March, 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf. Accessed 9 July, 2015.
Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 2008;70(13 Pt 2):1134–40. doi:10.1212/01.wnl.0000306410.84794.4d.
Temple R. FDA perspective on trials with interim efficacy evaluations. Stat Med. 2006;25(19):3245–9. doi:10.1002/sim.2631. discussion 326–47.
Dragalin V. Adaptive designs: terminology and classification. Drug Inf J. 2006;40:425–35.
Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012;13:145. doi:10.1186/1745-6215-13-145.
U.S. Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. February 2010. http://www.fda.gov/downloads/%20DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed 14 July 2015.
Elsasser A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, et al. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials. 2014;15:383. doi:10.1186/1745-6215-15-383.
Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304–12. doi:10.1212/01.WNL.0000286940.29755.61.
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55(3):853–7.
Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, et al. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015. doi:10.1097/WAD.0000000000000093.
Schneider S, Schmidli H, Friede T. Blinded sample size re-estimation for recurrent event data with time trends. Stat Med. 2013;32(30):5448–57. doi:10.1002/sim.5977.
Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67. doi:10.1016/S1474-4422(13)70102-9.
Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66(5):660–3. doi:10.1212/01.wnl.0000201182.60750.66.
Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334(7597):786. doi:10.1136/bmj.39136.682083.AE.
Committee for Proprietary Medicinal Products (CPMP). Points to consider on multiplicity issues in clinical trials. 19 September 2002. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf. Accessed 14 July 2015.
Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289(19):2554–9. doi:10.1001/jama.289.19.2554.
Montori VM, Busse JW, Permanyer-Miralda G, Ferreira I, Guyatt GH. How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: should I dump this lump? ACP J Club. 2005;143(3):A8.
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target No evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329–33.
Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152–8. doi:10.1001/jamaneurol.2014.3537.
Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012;11(5):467–76. doi:10.1016/S1474-4422(12)70059-5.
Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920. doi:10.1136/bmj.c3920.
Imitola J, Racke MK. Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? JAMA Neurol. 2015;72(2):145–7. doi:10.1001/jamaneurol.2014.3860.
Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med N Y. 2011;78(2):161–75. doi:10.1002/msj.20239.
Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014;31(11):1134–54. doi:10.1007/s12325-014-0167-z.
Editorial assistance and medical writing support in the preparation of this manuscript was provided by Andrew Kuhlman at Worldwide Clinical Trials.
All authors are paid employees at Worldwide Clinical Trials. The authors declare that they have no competing interests. The statements contained in this manuscript reflect the personal opinion of the authors and should not be construed as representing the opinions of Worldwide Clinical Trials.
MEB, PA and MFM all contributed equally to writing, editing and approving the final manuscript.
Dr. Beelke is board certified Clinical Neurophysiologist and Neurologist, and involved in the Clinical Development in Multiple Sclerosis for more than 12 years. He received his M.D. from the University of Genoa, Italy and a PhD in Sleep Medicine from the University of Bologna, Italy.
Dr Antonini received her M.D. from the University of Rome, Italy. She also has a PhD in Clinical Pharmacology. Her medical training experience includes an internship in oncology surgery at the Cancer Research Institute of Rome, Italy. In the current position at WCT Dr Antonini is responsible for scientific services delivery.
Dr. Murphy is a board-certified psychiatrist and pharmacologist, Research & Development Editor for American Health & Drug Benefits™ and a lecturer within the Master’s Program in Clinical and Translational Investigation of the Harvard Clinical and Translational Science Center.
About this article
Cite this article
Beelke, M.E., Antonini, P. & Murphy, M.F. Evolving landscapes in multiple sclerosis research: adaptive designs and novel endpoints. Mult Scler Demyelinating Disord 1, 2 (2016). https://doi.org/10.1186/s40893-016-0003-1
- Relapsing multiple sclerosis
- No evidence of disease activity (NEDA)
- Disease activity free (DAF)
- Adaptive design
- Primary endpoint

domain: medical


text:
I signed up to put my two cents in for the power battles but i keep finding more and more on this site. I had no idea there were forums on here until a bit ago. Even cooler that there's is a little art section. Feel free to drop a critique down though these have already been absolutely raped on another forum (brutally honest critiques...note me if you want that kind of tough love help... i can't guarantee you won't cry).
These are just wild bits from my mind.
Some pencil work.
ClayFace ala batman begins style
Rogue and G-man
promo for a friends new book, Cereal and Pajamas from Ape comics
TMNT love. Ratking and Baxter Stockman
Part of a three page vertical pinup.
Some colored stuff. I try to stay as far away from colors as possible unless theres money involved.
Some digital stuff (digi lines on the wacom tablet... don't do too many of these nowadays)
Okay, i really hope these links work. Feel free to harass me on dA if you're a member (not the site for good critiques).
I am a starving teacher (8th grade, American History). Don't be afraid to inquire about a commission. Okay, back to powers voting.
Oh, and some of these are available as prints. Which are fun to have... to...look at?
Post Edited:2007-09-29 16:01:55

domain: artistic


text:
Introduction: Yellow Citrine Faux Gemstone Points & Pendants
Citrine is a beautiful yellow quartz crystal often used to make jewelry. The most coveted citrine is lemon yellow with excellent clarity. These clear yellow gems are the most expensive citrine stones, but we can easily reproduce them in resin.
In this tutorial I'll show you how to create realistic citrine gemstone points, and turn them into gorgeous pendants.
Step 1: What You Need
Resin of your choice (clear) - I'm using polyester resin for this project
Mixing cups, stirrers, gloves
Yellow transparent alcohol dye
Gemstone point mold
Piece of parchment or wax paper
Newspaper, mat, or other surface protector
Great ventilation - I'm working outside
Jewelry findings - 2-3" headpins, beads caps, jump rings
Round nose pliers, Flat nose pliers
Step 2: Begin
Take out all your resin supplies and set them up so you don't have to find things with sticky hands. Pour about an ounce of resin into a mixing cup. If you're using polyester resin do NOT add the hardener yet. If you're using epoxy resin, mix a half ounce of each part for 1 ounce total. Only use UV resin if your molds are perfectly clear.
Step 3: Color
Different brands of alcohol dye have different concentrations, so start by adding only one drop of yellow dye to your resin. If it barely shows add another drop or two, once you see a light yellow tint, mix gently and thoroughly.
Step 4: Adjust Color
Keep adding 1-2 drops of dye at a time, and then stir again, until you reach a bright, light yellow. The exact tint is up to you - citrine comes in gradations from barely yellow to and darker, almost orange hue.
When you're getting close to the desired color, bring it into a different light. I was working in the shade, so I brought it into the sun to check the color.
Step 5: Hardener
If you're using polyester resin, now is the time to add a drop or two of hardener. (The more drops, the faster it cures.)
Step 6: Mold
Carefully pour the resin into your point mold. Make sure it gets all the way to the bottom without bubbles. If you do see a bubble or air pocket, poke it with a toothpick.
Step 7: Keep Molding
Pour resin into the rest of your point and gemstone molds. Set the molds on a flat surface.
If you have any resin leftover, pour it onto a piece of wax or parchment paper. This is so you can see how your resin is curing without disturbing your molds.
Occasionally test the thickness of the resin with the head part of a head pin.
Step 8: Wait
Step 9: Testing, Testing
Test the resin with a headpin occasionally until the resin has a jelly-like consistency. The headpin should be able to dent the resin before poking through.
When the resin reaches this stage, gently poke through the top of the point mold resin and insert the headpin about 1/4-1/2". If the resin is the right consistency, the pin will remain straight up and be permanently attached to the resin.
Repeat with all of your vertical molds.
Step 10: Wait Again
Leave undisturbed to cure the rest of the way.
You can use your extra resin to continue testing for hardness.
Step 11: Unmold
The "gemstones" will pop out easily.
The points will require some gentle coaxing. You can use the headpin to help pull the cured resin out of the vertical molds.
Step 12: Make a Pendant
Since the head pin is permanently attached, you can string any kind of bead caps and beads onto the wire for adornment. I used a filigree bead cone on my point, and a bead cap and beads on the cylinder. The bead cone was made from a thin metal, so I was able to bend it to fit the point.
When choosing the right findings, see if there's anything you need to hide, like the headpin.
Step 13: Secure Findings
To secure the caps, cones, and beads, you'll make a wrapped loop right above the top finding on each pendant as shown. (See step 6 in this earring Instructable for detailed wrapped loop instructions.)
Wrap the wire tail around the top of the cone or top bead. This will hold everything in place, but if you want extra security, you can add a drop of E6000 or other jewelry glue.
Step 14: Finish Pendant
Add a jump ring to each wrapped loop. Now your faux citrine pendant is ready for a chain!
Step 15: Enjoy!
These faux citrine points lend themselves to lots of possibilities:
You can either get the classic point molds or a variety of other shapes. You can use any assortment of findings or get creative and make your own. You can even experiment with using other materials for your cap like aluminum foil or fabric. Or forget about the caps altogether and just make a simple loop for hanging.
Have fun and let me know how it goes if you try this project!
Participated in the
Colors of the Rainbow Contest


text:
With fall in the air, the narrow window of time to race on the salt flats of Bonneville is rapidly coming to a close. However, that didn’t stop Chris Carr and the BUB Racing team from getting an LSR at last week’s Land Speed Shootout promoted by Mike Cook. Carr and the BUB Racing crew took their Streamliner Seven motorcycle up to a staggering 367.382 mph (unofficial). Going at one point 380 mph, Carr’s run is still pending official approval by the FIM. Click past the jump for a video of their record pass, some photos, and more.
Helping BUB Racing go so fast is their streamliner shell, which is constructed around their one-off motorcycle. With 3 liters of turbocharged displacement, the Streamliner Seven sports a proprietary 16-valve V4 motor that makes 525hp and 420lb•ft of torque. Making the motor standout even more is its “big-bang” firing order, which helps the bike hook-up with the slippery salt surface.
Carr’s record re-captures the fastest motorcycle title from Rocky Robinson and the Ack Attack Team, who set a speed of 360.913mph last year at the Land Speed Shootout. With the weather coming, it seems unlikely that Ack Attack will be able to answer back to Carr’s record this year.
Source: BUB Racing

domain: hobby


Also in this playlist...
This transcript is automatically generated
Stevie says those animals are are twittering -- some questions that jobs because the big issue today America is asking about jobs and employment we -- new numbers today that offer.
A mixed picture still about is it the labour market overall take a look at this number -- the private sector rising by a 1141000.
Last month that's according to the latest.
I'm most -- is new jobs were created by the way by small and medium sized companies are gonna talk about that in a second another report.
Should plans layoffs in the private sector shooting up by 60% last month.
That's according to the outplacement firm challenger Green Christmas.
I -- cuts there are now rising three months in a -- hitting the highest level in sixteen months and so there's some concern here about.
Jobs how to get one marks it ally is the founder and CEO of the latter's -- on how to recognize -- commercials out there -- you help people find jobs mark.
That's what you DO.
That's who we -- we help people find professional jobs.
At all levels and just a specialized and helping people when they're looking for -- the next transition in the career whether it's increase in -- Or title or responsibility.
Have you been operating how many years we've been at this eight years now -- you've seen the economy -- -- into every sash and restarted a recession we went through rumored -- -- recession again so it's cyclical isn't ever viewers have this question they wrote in asking -- about whether or not you think we're actually in a double dip recession in the job market.
We haven't seen that yet know the unemployment numbers today from ABP were not remarkable.
Which is actually the problem -- not remarkable at this point in a recession and a recovery we ought to be seeing that the numbers are getting a lot better a lot quicker.
And we're not seeing that so.
It's not going as fast as we'd like and we have to wonder is itself.
You're selling point initially was that you -- catering to people that were looking for jobs with a 100000 dollar salary error or higher which.
Sounds good right those advances six figure jobs that a Lotta folks want -- there.
First of all.
Are -- -- jobs out there and and where exactly are today.
Tons of hundred K plus jobs out there and the thing that we forget in a recession is that even though there are layoffs and even though there is.
You know -- relatively high unemployment rate.
Most -- his replacement hiring.
Most of the times when companies are hiring.
They're hard to replace somebody who's -- the -- to fill a need for somebody has been transferred to the vast majority of -- his replacement hiring so there's always.
A ton of jobs -- we have over 50000.
If that's a question of where -- what industries are are really the ones that you are placing people on it.
Was so the the the big picture is obviously a lot of -- for manufacturing moved overseas.
Less and less the job openings out there are in the manufacturing sector and the more more -- the technology services in the thinking jobs sector.
So jobs -- where people -- professional services or design or.
Doing things were -- working behind a desk rather than we're gonna factory.
So in these times that we see -- -- it out of work for.
For months on end that's have to get back into the job market when you've been -- you're coming from a place for you to have a job -- what.
What is the key that you're seeing.
That you get these candidates you help connect them with the right job the what what is really helping us candidates.
So lot of times when when I talked people looking for jobs as -- well I'm looking to do anything I can do anything and that's great but it's also a problem because companies are hiring.
A VP of anything I generalists they're they're they're hiring a VP of marketing -- -- -- director of sales.
You have to actually narrow your focus to be successful.
In this job market because there.
There isn't just one or two other candidates out there.
-- the same job in that you are there is one dozen to a dozen -- hundred that are -- need to be specialized and communicate what's different about you.
So that you can get that position.
Markets -- question about pay -- and asked you about that during the break put it back out.
Over our chat and twitters we get that that question -- -- thank you so much for -- -- appreciate so much mark platters are content John and I'm gonna ask him how I can get Neil Cavuto is job.
Filter by section


text:
Kenya leads the pack in turning the tide against climate change
Nairobi is implementing smart agriculture strategy that seeks to reduce carbon emissions
By ZEYNAB WANDATI
As disillusioned Kenyan sugarcane farmers seek other lucrative activities, the Climate Finance Unit in the National Treasury says it is looking for funds to make the crop climate resilient crop.
“This is part of the climate smart agriculture strategy that Kenya has adopted,” said Peter Odhengo, a senior policy analyst of climate finance at the National Treasury.
Kenya is among the first countries to design and implement a climate smart agriculture strategy. The initial phase of the project involves a $230 million programme focusing on 23 counties in arid and semi-arid lands. This project is being funded by various development partners, among them the World Bank.
Climate proofing economies was one of the topics at the 24th United Nations Framework Convention on Climate Change in Katowice, Poland.
“We are here to make our voice heard. We want to get the rich countries to commit to increase funding for building resilience in vulnerable countries such as Kenya,” said Mr Odhengo.
“Countries such as Kenya have climate change laws and policies, the only such laws on the whole continent. Our job now is how to ensure that we leverage these policies to ensure that the people most affected by the impact of climate change are adequately compensated for their losses,” said Mithika Mwenda, the executive director of the Pan African Climate Justice Alliance.
It is not clear how much money Kenya needs to climate proof its economy, but, according to Mr Odhengo, “it is so much that the government alone cannot finance it.”
“If you look at the National Climate Action Plan 2018-2022, it is trillions of shillings, while the the first climate change assessment report of 1998 quotes Ksh1.5 trillion ($15 billion) over a 10-year period,” said Mr Odhengo.
In 2010, the global fund — Green Climate Fund was set up to help countries such as Kenya go green. In order to manage the money from a fund such as this, Kenya created a Climate Finance Unit in the National Treasury.
“We have started tracking climate finance flows, where it goes, and who handles it while measuring the impact using simple tools such as the numbers of livestock that can withstand climate shocks and the amount infrastructure that was destroyed by harsh weather,” added Mr Odhengo.
In the past five years, the Green Climate Fund has disbursed more than $500 million to Kenya, some of which came from the World Bank Climate Investment Fund. Among the projects funded are geothermal power and M-kopa Solar.
In February, Kenya, through Sessional Paper No. 3 on National Climate Finance Policy, provided guidelines for the use of money intended for climate-proofing of the economy. Kenya is the first country in the world with such a policy. In July, Mexico and some Caribbean countries reached out to Kenya for help in designing such a policy.
The GCF requires beneficiaries to put in place strict traceability mechanisms that will ensure the money goes where is intended.
“There is what is called a delivery partner. The money doesn't go directly into the hands of any corrupt individual. This accredited entity is monitored by the national government to 1.5°C above pre-industralisation level.
According to the Global Carbon Project, emissions have continued to rise since 2015 and are projected to continue in 2018, by more than 2 per cent to hit a new record, mainly due to sustained growth in oil and gas use.
This growth in global CO2 emissions puts the goals set out in the Paris Agreement in jeopardy. According to the intergovernmental Panel on Climate Change to limit warming below 1.5°C, carbon emissions should decline by 50 per cent by 2030 and reach net zero around 2050. Current country commitments lead to +3°C of warming, well above the Paris Agreement goals.
Global fossil carbon emissions — fossil fuels, industry and cement — grew at over three per cent per year in the 2000s, but growth has slowed since 2010, and from 2014 to 2016 emissions remained relatively flat.
However, the climate pledges currently tabled by countries — Nationally Determined Contributions (NDCS) — are still viewed as not good enough, because they will result in global temperatures rises of between 2.7°C and3.5°c. Africa says this will be catastrophic for its countries because it will mean more droughts and floods.
Kenya's climate pledge is an eightpage document that is pegged on the Climate Change Act of 2015, which seeks to cut the country's emissions by up to 30per cent by 2030. Kenya hopes to achieve this through reforestation activities and climate proofing the agriculture sector.
Workers load bags of green tea leaf at the Kitumbe Aerial Rope Way Conveyance Technology in Kericho, which has reduced carbon emissions.

domain: politics


text:
CRANBERRY, Pa. — A couple of major changes happened in the professional women's hockey landscape in the spring of 2019
On March 31, the Canadian Women's Hockey League announced that it would cease operations on May 1, after 12 seasons. The six-team league had paid its players a stipend in its final two seasons in existence. The CWHL's folding left the five-team National Women's Hockey League as the only organized professional women's league in North America.
© 2020 DK Pittsburgh Sports

domain: history


text:
Microchip manufacturing powerhouse Advanced Micro Devices (AMD) responded to an Intel statement about a recent security flaw, stating that their chips are not affected by said flaw.
AMD is expected to issue a security research on the security flaw on Wednesday. The company provided an initial statement saying that the team responsible for the security research isolated three variants targeting speculative execution.
The threat and response to the three variants may differ depending on the microprocessor company, further adding that AMD is not susceptible to all three variants. AMD also stated that since AMD’s chip architecture differs from other chip manufacturers, the flaw may pose zero risk to the company’s processors.
AMD increased slightly following AMD’s initial statement. However, the stock dropped after Intel released its statement earlier.
The Register considered that the flaw didn’t have an effect on AMD chips but rather predominantly affected chips from Intel.
However, on Wednesday, Intel’s public statement showed that the flaw is not restricted to Intel processors only, suggesting that other manufacturers’ components might be affected too. Intel is currently cooperating with other companies, which includes AMD, to find a solution to the issue.
AMD’ first statement indicates that it is cooperating.
As stated by AMD, the company is currently working together with other manufacturers to study and counter the speculative execution attack recognized by a security research team to guarantee the safety and protection of their users.
Brian Krzanich, CEO of Intel, spoke about the conversation with Jon Fortt of CNBC, stating that Google was the first to inform Intel about the issue, and to Intel’s knowledge, the flaw had not yet been studied.

domain: news


PARIS — Zilli, the French luxury men’s wear brand, will open a New York flagship this fall.
The 2,700-square-foot boutique will be in the Four Seasons Hotel at 57 East 57th Street, and will be accessible from both the street and the hotel. The store had previously been occupied by the luxury Italian brand Brioni.
The New York unit will be the third Zilli store to debut this year, following the May opening of a location in Porto Cervo, Sardinia. Another boutique is set to open in Brussels in September.
The privately owned, Lyon-based company — whose hyper-expensive products include alligator sneakers that retail for 2,040 euros, or about $2,900 — already has 37 company-owned stores and wholesales to about 100 doors. The new store will include a bespoke tailoring section.
Zilli said it is investing more than $2 million in the New York boutique, which will be its second in North America. The firm has operated a location in Montreal since 2007.
Zilli’s 2008 sales totaled 68.2 million euros, or $100.3 million at average exchange rates.


text:
Lyman Whitaker ~ Wind Sculptures
A native of Utah, Lyman has been a practicing sculptor for over fifty
years. He is internationally known as a master in the kinetic sculpture
discipline. Wind Sculptures – his main focus since the mid-1980’s –
are innovative, artistic, and responsive to their natural surroundings.


text:
Field Detection of Drugs of Abuse in Oral Fluid Using the Alere™ DDS®2 Mobile Test System with Confirmation by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).J Anal Toxicol. 2018 Apr 01; 42(3):170-176.JA
The collection and analysis of drugs in oral fluid (OF) at the roadside has become more feasible with the introduction of portable testing devices such as the Alere™ DDS®2 Mobile Test System (DDS®2). The objective of this study was to compare the on-site results for the DDS®2 to laboratory-based confirmatory assays with respect to detection of drugs of abuse in human subjects. As part of a larger Institutional Review Board approved study, two OF samples were collected from each participant at a music festival in Miami, FL, USA. One OF sample was field screened using the DDS®2, and a confirmatory OF sample was collected using the Quantisal™ OF collection device and submitted to the laboratory for testing. In total, 124 subjects participated in this study providing two contemporaneous OF samples. DDS®2 field screening yielded positive results for delta-9-tetrahydrocannabinol (THC) (n = 27), cocaine (n = 12), amphetamine (n = 3), methamphetamine (n = 3) and benzodiazepine (n = 1). No opiate-positive OF samples were detected. For cocaine, amphetamine, methamphetamine and benzodiazepines, the DDS®2 displayed sensitivity, specificity and accuracy of 100%. For THC, the DDS®2 displayed sensitivity of 90%, specificity of 100% and accuracy of 97.5%, when the threshold for confirmation matched that of the manufacturers advertised cut-off. When this confirmatory threshold was lowered to the analytical limit of detection (i.e., 1 ng/mL), apparent device performance for THC was poorer due to additional samples testing positive by confirmatory assay that had tested negative on the DDS®2, demonstrating a need for correlation between manufacturer cut-off and analytical reporting limit. These results from drug-using subjects demonstrate the value of field-based OF testing, and illustrate the significance of selecting an appropriate confirmation cut-off concentration with respect to performance evaluation and detection of drug use.

domain: literature


text:
Most people depend on luck to choose winners and if they occur to do just that, they attribute it to, well, luck. But if you want to go beyond becoming fortunate and choose winners most of the time, then you need to get a betting method that has been proven as a sure winner. Luckily for you, John Morrison has developed 먹튀사이트조회 Champ that matches this kind of a description.
For some individuals, 먹튀사이트조회 is more than just a way to spice up a favorite previous time; it is big company. All more than the globe, bets are placed on lacrosse, cricket, football, soccer, baseball, and every other sport you can title. Some people win large, some people win consistently, but it’s usually the publications that arrive out on leading. Allow’s take a further look at what sports betting is all about, and some of the burning concerns people have on the topic.
Sports teams are not all created equally. Often, the most likely winner of a sport is known prior to the game is even performed. Allow’s consider the University of Alabama Crimson Tide football team, 1 Future of sports betting company college football’s most dominant teams. And allow’s assume that they are playing against the University of Toledo Rockets soccer team, which hails from a a lot smaller sized and much less set up college. The Crimson Tide would nearly certainly get. Ought to the Toledo Rockets pull off an upset it would be a major event, likely garnering national headlines.
Aside from becoming educated about the system and the whole activity where you’ll be betting, it would still be important that you maintain in thoughts to wager properly. Some on-line 먹튀사이트조회 websites have a money administration system that can help the bettors track their cash so that they won’t wager much more than what they want to lose.
Whether you’re heading up the sports pool with a small team of buddies or handling the betting for your entire business, utilizing an online instrument will help make the procedure 먹튀사이트조회 a lot simpler, saving you time so you can, you know, get work carried out while you’re at work.
One of the best ways for you to encounter this engaging way to bet on your favorite racing and sporting events is to get acquainted with online Sports betting. Nevertheless, in order to very best consider advantage of all that 먹튀사이트조회 has to offer, you require to know a little more about it.
Check the picks that are «in the second» to make an knowledgeable choice about putting your wager. Even if it is not your favorite team Future of sports betting company-wise, it might turn out to be your favorite group betting sensible. Any knowledgeable advantage you can get for free is a valuable benefit. That way the cash you have to make winning wagers raises. So, get as much solid suggestions as you probably can for totally free. That is truly getting value for your cash. Cash you can use for more knowledgeable betting!
One way you can put together your self for sports betting is familiarising yourself with the game. Collect as a lot information as feasible and learn about the winning information of the team you are preparing to location a wager. Understanding the winning and dropping statics will help you select your group wisely. When you location a wager properly, you can go on a winning streak on a normal basis.
The final common mistake to be mentioned is not keeping your extremely personal personal betting records for on-line sports betting. If you take sports betting online as a severe company, not only ought to you have a separate bank account for it, you require to maintain a document of all your previous betting as well. If not, you will remember most of the wins you had but you will have a great deal of trouble remembering the losses. This info is essential in your Future of sports betting company bets.
One way you can put together your self Search for sports betting companies sports betting is familiarising your self with the sport. Collect as much information as possible and learn about the successful records of the team you are preparing to location a wager. Understanding the successful and dropping statics will help you select your team properly. When you place a wager properly, you can go on a successful streak on a normal foundation.
A Search for sports betting companies method is any technique you use frequently when you are placing money down on an event. It doesn’t matter whether or not we are talking about wagering on Blackjack or on the Cowboys’ game, or even if it works or doesn’t, a system is any set of rules you use regularly when putting bets.
Having a good betting system and a idiot evidence betting strategy will regularly give you a great winning typical in sports betting. Knowing what groups have a much better opportunity of successful is only part of the story. Maximizing your winnings and minimizing your losses is the other part.
It requires you to make eight Parlay bets on 6 groups, 3 of which are favorites. If 1 Future of sports betting company the favorites shed by exactly 1 operate, you shed the bet. So a lot for becoming infallible.


text:
Abstract: This handout for breastfeeding mothers explains the benefits of using a breast pump, what to expect when pumping, how often to pump, and how to choose a breast pump. This document is a chapter in the birth book "Caring for Yourself and Your New Baby."
The health education materials accessed through this site are not intended
to be a substitute for professional medical advice, diagnosis, or treatment.
Always seek the advice of your doctor or other health care provider with any
questions you may have about a medical condition.
If you think you have a medical emergency, call your doctor or 9-1-1 immediately.
Top | Back | UW Medicine | UWMC | Main | Admin | Contact Us
UWMC Health Online ver. 4.2.0
Please see the "Who To Contact" page for list of people to contact with problems or questions with this site.
Copyright © 1998 - 2017 University of Washington. All rights reserved. Please honor our copyrights and disclaimer.
Last reviewed: 1/28/2004. Last updated: 1/28/2004.

domain: health


text:
The restaurant is very nice. Despite being on a busy street, strategic placement of bushes and flowers make it quiet and pleasant, and somehow they make everything smell faintly of lemongrass, while the street 10 feet away smells... distinctly less nice.
I had the best fish and chips of my life here. They were not traditional - the fish was fried in fritters - but the batter was light and flavorful and the fish was lovely. Definitely recommended.
My main complaint is the cost. I spent 35 USD for fish and chips and a Tusker. Mostly I found this annoying because most everywhere else in Nairobi, menu prices include taxes, but here they were added, along with a service charge. Worthwhile for a rare treat, but not an everyday experience.
If you own or manage Lord Delamere Terrace, register now for free tools to enhance your listing, attract new reviews, and respond to reviewers.

domain: travel


text:
The first annual Lake Campus Research Symposium was held in 2016.The event was centered around 20+ research projects presented by 30+ faculty and students and was attended by over 150 people from the campus community.
The internal grants and scholarly expenses program that was launched in 2015 continues to provide research support to both faculty and students.
Numerous research related workshops on building proposals, writing research papers,and identifying grant support have been held.
Faculty and faculty mentored students produced 100+ units of research spanning peer reviewed journal articles, contracts and grants, books, book chapters, book reviews, novelettes, reference works, short fiction works, plays, and scholarly presentations.
For more information, please explore the research reports from the campus over the past few years!
- 2018 Research Symposium
- 2017 Research Symposium
- 2016 Research Symposium
CELINA, OH – Wright State University – Lake Campus faculty, staff and students participated in WSU-Lake Campus Annual Giving Tuesday Food Drive. This event is in its fifth year and 2018 was the most successful Food Drive. On November 1, donations began to be collected throughout the Lake Campus family. On Nov. 27, Giving Tuesday, the final calculation was tallied....
The Wright State Lake campus is focusing on one word right now, “growth”.
This year, Lake Campus has set a record for enrollment with over 1,500 students, plus they have grown the number of degree programs that they offer in the past few years. Part of that growth is a 2.8 million dollar building extension project. The new 7,000 square foot addition that will include a library, science education classroom and research lab, and nursing classrooms.
CELINA, OH – Construction on the Extension Building Project at Wright State University – Lake Campus began this week. This renovation and construction project will add over 7,000 square feet to Andrews Hall and will include a new Library and Technology Center, Nursing Lab and Science Education Lab. The $2.8 million project is slated to be complete by the Fall of 2019.
Muhlenkamp Building Corporation in Coldwater, OH, will serve as the general contractor for this project. Funding for...
CELINA, OH – Wright State University – Lake Campus kicked off Fall Semester on Monday, August 27, 2018 with its highest enrollment to date. Staff, faculty, and student employees welcomed the record-breaking Lakers into the academic year with a variety of free activities.
CELINA, OH – Wright State University – Lake Campus held its third annual convocation on Thursday, August 23rd, led by Lake Campus Dean and Chief Administrative Officer Jay Albayyari, Ph.D.
At Convocation Lake Campus faculty and staff came together to reflect on accomplishments from the past academic year and prepare for the upcoming semester. Albayyari gave a presentation focusing on budget, enrollment, development and giving, and capital improvements. Albayyari also...

domain: library


text:
Packer swimmers take 9th in Big Nine meetPublished 12:51am Sunday, October 28, 2012
MANKATO — The Austin girls swimming and diving team took ninth at the Big Nine meet in Mankato East Saturday.
Austin’s Autumn Laury took fifth in diving and Helen Heimark took sixth in the 100-yard freestyle.
The 400-yard freestyle relay team of Lindsey McAlister, Mikayla Finney, Merideth Fritz, and Heimark took sixth, and the 200-yard medley relay team of Maddie Kinney, Emily McAlister, Fritz and Lindsey McAlister took seventh.
200-medley relay: Maddie Kinney, Emily McAlister, Merideth Fritz, Lindsey McAlister (seventh, 2:01.88)
200-freestyle: Helen Heimark (10th, 2:05.72)
50-freestyle: Mikayla Finney (12th, 26.78)
Diving: Autumn Laury (fifth, 312.00)
100-butterfly: Merideth Fritz (10th, 1:06.73); Emily McAlister (15th, 1:08.08)
100-freestyle: Helen Heimark (sixth, 55.99); Mikayla Finney (ninth, 58.02)
500-freestyle: Rachel Vos (15th, 5:51.29)
200-freestyle: Mikayla Finney, Lindsey McAlister, Merideth Fritz, Helen Heimark (fifth, 1:45.12)
100-backstroke: Maddie Kinney (16th, 1:09.61)
100-breaststroke: Emily McAlister (12th, 1:16.87)
400-freestyle relay: Lindsey McAlister, Mikayla Finney, Merideth Fritz, Helen Heimark (sixth, 3:54.26)

domain: sports


Q: I have a 1970 Lotus Europa S2. It’s a mid-engined, rear-wheel-drive car.
With a little cutting and welding, I managed to take a Ford 302 (bored .30 over) and nestle it snugly behind the firewall. The engine runs like a charm, but now I need to find a transmission that will match the Ford engine and line-up with the rear wheels.
I know the Ford GT40 from the 1960s had the same drivetrain as my Lotus now carries, but I don’t recall what kind of transmission it had. Can you help me out?
Also, what engine components would I need to upgrade if I were to install a T3/T4 hybrid turbo with a 57-trim compressor wheel, kicking out 25-28 psi of boost? The engine is stock except for the overbore and matching rings.
A: That’s easily the most interesting combination we’ve heard in a while. The best part, is that the answer to your first question is also pretty interesting.
The De Tomaso Pantera was powered by a Ford Cleveland V8, and it used the same five-speed ZF transaxle as the GT40.
The ZF is very strong and has a limited-slip design. An 11-inch clutch plate is used with a hydraulic master cylinder for clutch linkage. If you can’t scavenge one of those, Ford Racing used to offer a GT40 transaxle (M-7003-GT), though it has been discontinued and would now likely cost well more than your project is worth.
As for the turbo upgrade, you’ll need to do a number of things.
The crankshaft needs to be replaced with a 4340 steel crankshaft, and the connecting rods need to be upgraded to H-beam rods. You’ll also need forged pistons, and you’ll need to drop the compression to 7.5:1 or 8.0:1 in addition to opening the ring gap.
Finally, you’ll need a camshaft designed for the turbo, and the entire rotating assembly will need to be balanced.
I built a mid-engine sbc 41 Thames 1/2 ton in the 70s using a Corvair 4spd transaxle. I went through 5 of them over the years due to putting power to the glide side of the gears (running backwards). The kit car industry found my solution by using the 2002-2005 porche boxter S 6spd transaxle behind v-8 power. They go for an affordable $1500 and handle 400 ft-lbs torque . Use off road CV 300M joints.
Enjoy your ride my friend.
That is an outstanding solution to a unique problem–thanks for the feedback David!


text:
Your vehicle accelerates automatically, which is why normally all you need to do is worry about changing lanes. This is easy enough to do, just by pushing buttons from left to right on your screen. Next to these buttons, is where you'll find the jump button along with the ones that let you activate your special skills.
The races in Rush N Krush aren't overly realistic by any means. Actually, in most games you'll get to activate mighty special attacks that allow you to completely destroy any traffic that gets in your way or bust out some huge spikes that'll clear the way of any rival that crosses your path.
Even though in the beginning you'll only need one vehicle, you'll have the opportunity to unblock many more. In fact, the game allows you to buy tons of improvements and additional abilities for your cars. Of course, you'll also need to earn cash in each race in order to access this content.
Rush N Krush is a racing game with certain elements that'll easily remind you of Destruction Derby along with some aspects typical to the 'endless runner' genre. The visuals in this game, while nothing extraordinary, are actually pretyy spectacular when you're rushing down the highway at full speed through the super dense traffic jams.
Requires Android 4.0.3 or higher.


It has now been over a year since the last major release of YAWAST, but today I am happy to release version 0.7, which is one of the largest changes to date. This is the result of substantial effort to ensure that YAWAST continues to be useful in the future, and add as much value as possible to those performing security testing of web applications.
If you are using the Gem version, simply run
gem update yawast to get the latest version.
One of the headline features is that YAWAST now supports producing JSON output via the new
--output=<file> parameter. This will create a JSON file that can be used to record the actions of YAWAST in more detail, and be used in reporting automation. The goal of this feature is to capture all of the information that is needed to produce a report automatically.
If you specify
--output=/path/., YAWAST will automatically generate a file name based on the domain name and current time.
The overall structure of the JSON output shouldn’t change, but the details included may change over time as the output is refined to make it as useful as possible.
Enhanced Vulnerability Scanner
The other major change in this version is the new vulnerability scanner, which adds a number of new checks, and opens the door to more easily adding checks in the future. This is currently accessed via the
--vuln_scan parameter, as this is seen as a beta-level feature; when used without that parameter, YAWAST behaves as it has in the past. In the future, this will become of the default behavior, once it’s clear that it is stable.
It is recommended that you use
--vuln_scan unless it is causing issues for you (and if it does cause issues, please open an issue).
One behavioral change is that the new
--spider option works differently in each mode;
--vuln_scan will always spider the site, so in that mode,
--spider simply adds printed output to the UI listing the URLs found.
This new scanner leverages Chrome via an automated interface to perform certain tasks, that can only be properly tested by browser interaction; this adds some new dependencies, though the application should fail gracefully if these aren’t present.
The YAWAST Docker image has been updated to work with this new feature, making it the easiest way to use it.
User Enumeration via Password Reset Form (Timing & Response)
One new experimental feature that I would like to point out is that YAWAST will attempt to use the target application’s Password Reset Form (specified via
--pass_reset_page) using Chrome automation to capture the difference between a valid user (specified via
--user) and a randomly generated invalid user. It will compare the responses and display a diff of the changes between the two.
YAWAST will attempt to automatically identify the form field that captures the username / email address, if it fails to find the field, it will prompt you to provide the name or id.
It will run this procedure a total of 5 times, and capture of the timing that each request took, to determine if timing information can be used to determine valid users.
[V] Password Reset: Possible User Enumeration - Response Timing (see below for details)
Difference in average: 368.6ms Valid user: 736.15ms Invalid user: 367.55ms
Valid Users Invalid Users
Here is a list of the changes included in this version:
- #38 – JSON Output Option via
--output=(work in progress)
- #133 – Include a Timestamp In Output
- #134 – Add options to DNS command
- #135 – Incomplete Certificate Chain Warning
- #137 – Warn on TLS 1.0
- #138 – Warn on Symantec Roots
- #139 – Add Spider Option
- #140 – Save output on cancel
- #141 – Flag –internalssl as Deprecated
- #147 – User Enumeration via Password Reset Form
- #148 – Added
--vuln_scanoption to enable new vulnerability scanner
- #151 – User Enumeration via Password Reset Form Timing Differences
- #152 – Add check for 64bit TLS Cert Serial Numbers
- #156 – Check for Rails CVE-2019-5418
- #157 – Add check for Nginx Status Page
- #158 – Add check for Tomcat RCE CVE-2019-0232
- #161 – Add WordPress WP-JSON User Enumeration
- #130 – Bug: HSTS Error leads to printing HTML
- #132 – Bug: Typo in SSL Output
- #142 – Bug: Error In Collecting DNS Information


text:
Hi! Simply click below and type your query.
Our experts will reply you very soon.
Day 1: Arrival Kolkata
On arrival at Kolkata Airport/ Hwh Railway station, our representative will be there to assist you and transfer you to your already booked hotel. Check in to the hotel. The evening is free at leisure for shopping. Enjoy an overnight stay at the hotel in Kolkata.
Day 2: Kolkata Local Sight Seeing
After breakfast in the morning, we will leave for a full day city tour of Kolkata. We will be visiting High Court Building, Oldest Catholic Church in Calcutta, Howrah bridge, Vidyasagar Setu, National Museum, Victoria memorial, Kali Mandir, etc. Thereafter, we will return back to the hotel for an overnight stay.
Day 3: Kolkata – Puri Via Bhubaneshwar
In the morning after breakfast, we will transfer to Kolkata airport/ Hwh rly Stn to catch the flight or board train for your onward journey to Orissa. On arrival at BBI/BBS, our executive will be there to assist you and transfer to Puri, which is famous for Lord Jagannath & magnificent Golden Beach. On arrival, check in to the hotel. The evening is free at leisure for shopping. An overnight stay at the hotel in Bhubaneshwar.
Day 4: Puri
After breakfast in the morning, we will visit the Lord Jagannath Temple & other temples in & around Puri. The afternoon is free at leisure and you can visit the long stretch of golden beach, shallow enough to walk out a long distance with fantastic surf. Enjoy an overnight stay at the hotel in Puri.
Day 5: Puri – Bhubaneshwar
Today early in the morning, check out from the hotel and leave for Bhubaneshwar. On the way, you can visit the Sun temple at Konark. Later, we will proceed to Bhubaneshwar. On arrival at Bhubaneshwar city, get a direct transfer to Bhubaneshwar airport/railway station to board the train or catch the flight for onward destination.
Terms & Conditions :* Some Advance Percentage of total booking amount * Airfare/Transport fare to be paid full at one time in advance.~^#^~* Upon cancellation, refund will be made after deducting the Retention Amount. * Retention Amount varies as per the number of days left before your package start date. ~^#^~


text:
Bar Harbor Totes Pattern, Aunties Two Patterns
You May Also Like
Bar Harbor Totes Pattern, Aunties Two Patterns Details
Use the Bar Harbor Tote Pattern by Aunties Two Patterns to create these stylish, sophisticated bags. These elegant homemade totes can be made using any fabric you like and Bosal's In-R-Form Single-sided Fusible Interfacing. The Bar Harbor Tote Pattern includes instructions for making two different sized bags. The medium-sized finished bag measures 16" wide x 13" tall x 6" deep, and the large bag measures 18" wide x 13" tall x 6" deep.
- Skill Level Intermediate


$125 · Thule 510 “Big Mouth” Upright Rooftop Bicycle Carrier
Two Thule 510 aluminium bicycle carriers for sale. Excellent for carrying road bicycles, hardtail mtb's, bmx's and so on. Folding arms with soft grip clamp will keep bike upright during transport. When not in use, the arms lay flat and can be left on roof. Can attach to most crossbars with U-bolts, that are commonly found at hardware stores. Asking $125 each, or $200 for the matching pair. Used, but in good condition.
* The Big Mouth closure optimizes clamping pressure
* Fits bike frames up to 95mm diameter.
* Extruded aluminum tray
* Polypropylene and rubber clamp jaws
* Measures 54" long by 3" wide
Note: There are no keys for the built-in locks; a key can be cut at any city locksmith for under $15.
|Details||Last hour:||Last 24 hours:||All:|
|Posted||July 19, 2018|
|Expiry||August 18, 2018|


text:
Well, I just finished this book by Immaculee Ilabagiza. She is a young woman, actually about my age I guess, who miraculously survived the mass murder of the Tutsi people of Rwanda in 1994. Her story is difficult, but beautiful. I encourage you to read it, for many reasons. Understanding what happened in this holocaust is important, but on a spiritual level, there are things we need to learn from her about faith in suffering. Her story is a modern day example of how you can lose everything, and at that point be given a chance to understand more of the Bible and more of an intimacy with God than you ever would have in a land of safety and plenty.
There were times in reading this book I was shaking with rage, as I learned more details than I could really bear to know. And that rage is really what this book was about; it was about how generations of hatred live on, with lies whispered into their ears, rumors of blame. There is so much need in Africa, and so the cycle begins: There is suffering for a multitude of reasons, then many of those in suffering are so mad that they learn to hate the people they think are responsible for their lack, then after years of the lies (or maybe its true, maybe certain people like their government are responsible for their suffering) they believe those people aren’t even people. And when we believe someone else isn’t an equal human being, we ourselves stop acting as decent human beings. As generations carry these grievances, all started by satan who lives for this confusion and hatred and slaughter, thousands of people have the capability to cross their front lawn to kill their neighbors–all in an effort to have more jobs or food or security or safety for themselves–and this is part of the story of how the Rwandan Holocaust happened.
In my heart, (which as I said felt a lot of rage in reading this book) and in the hearts of those survivors and their children and their children who will walk the ground of Rwanda, or Germany, or even the United States,–who will continue to visit graves, who will still live in terror sometimes at the evil on the earth, who will possibly teach their children the same fear and self-reliance and sadness they themselves still suffer from–there must be a change. I pray for a healing, and this healing only–ONLY–comes through a personal encounter with Jesus and the truth of God’s Word. I have felt this so many times, and it is even more confirmed now, whatever we have to do to make a person safe, warm, fed, we need to do it, with the heart of God on our sleeve. We need to tuck them in covers and say this is Jesus with His arms around them, as Sweet Sleep does when they give beds to orphans. We need to rescue women who are numb and lost because of their current occupation of forced prostitution and like the International Justice Mission, give them spiritual mothers who can speak worth and promise into their lives again just like our mothers did. Damaged and broken people cause more damage and brokenness. They need Jesus, and in every blanket, every counseling session, every grain of rice, He can be clearly represented. World peace isn’t coming…Jesus is coming! Until He does, I want to know Him well, and trust He will make us vessels for others to also know Him well…know Him so well that “all of a sudden they are unaware of these afflictions eclipsed by glory” (J.M. McMillan/2 Cor. 4:16-18)
I pray for us to have these things Immaculee wrote about: Such a deep understanding of God’s personal relationship with us, deep enough to know all is well either in life or in death, deep enough to let go of this temporary life when the day comes. Such a deep understanding of Jesus’s words on the cross, “Father, forgive them, they don’t know what they are doing”, deep enough to face people who have done things worse than rabid animals would and just plead with God to bring them to their knees in repentance so they could be saved from His wrath.
Souls are so fragile. We have to love.